基本信息
views: 2
Career Trajectory
Bio
Pedro P. Lopez-Casas joined CNIO on July 2019 as Senior Scientist. I'm involved in the development of projects related to Prostate Cancer carcinogenesis and novel therapeutic approaches. Taking advantage of cutting-edge technology related to Precision Medicine (Next Generation Sequencing).
Ph.D. in 2000 under the supervision of Professor Dr. Lucas Sánchez at the Department of Cell and Developmental Biology in the Biological Research Center (CIB, CSIC), focused on the genetics and molecular biology of reproduction in invertebrates (Drosophila as model organism).
Postdoctoral training from 2000 to 2006 at the Molecular Biology of Gametogenesis Lab (Spanish National Research Council, CSIC), led by Professor Dr. Jesus del Mazo (Mentor). I was focusing on the regulation of gene expression in mammalians (Mouse as model organism).
Director of the R&D Laboratory at the "HM-Hospitales" from 2006 to 2009. I turned my research focus on Translational Oncology, giving support to the research projects within the “Clara Campal” Comprehensive Cancer Center. The achieved objectives were:
1) Founding a Mouse-based Preclinical Program (Patient-Derived Xenograft, PDX).
2) Founding a Human Tumor Biobank.
3) Involvement in developing an Early Clinical Trials Unit (Phase I).
Staff Scientist at the Spanish National Cancer Research Centre (CNIO) from 2009. My role was as Managing and Scientific Organizer of the Gastrointestinal Cancer Clinical Research Unit. The research focus of the Unit was the development of new therapeutic strategies in pancreatic cancer. My activities:
-Continuing a Mouse-based Preclinical Program.
-Executing and reporting National and International Competitive Research Projects.
-Collaboration with many Pharma and Biotech Companies from the US and Europe.
-Scientific guiding for all the personnel in training.
-Teaching in Masters and Animal Science Courses.
Awarded with the following accreditations by the ANECA institution in Spain: "Profesor de Universidad Privada", "Profesor Ayudante Doctor" y "Profesor Contratado Doctor".
Translational Research Director at Bioncotech Therapeutics (now Highlight Therapeutics), a CNIO spin-off, from 2018. I participated in the development of the lead drug candidate BO-112 (a best-in-class RNA-based therapy), which has been demonstrated to initiate a powerful immune response, turning ‘cold’ tumors ‘hot’ and now being tested in Phase II trials.
Currently, I'm back again to my former position at CNIO, as Staff Scientist, within the Prostate Cancer Clinical Research Unit.
Research Interests
Papers共 83 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
D Olmos,D Lorente,D Alameda,C Cattrini,N Romero-Laorden,R Lozano,P P Lopez-Casas, A Jambrina,C Capone, A M Vanden Broecke, M Trevisan,S Van Sanden,
Annals of oncology : official journal of the European Society for Medical Oncologyno. 5 (2024): 458-472
David Olmos,David Lorente,Daniel Alameda,Carlo Cattrini,Nuria Romero-Laorden,Rebeca Lozano,Pedro P. Lopez-Casas,Camille Capone, Anne Marie Vanden Broecke, Marco Trevisan,Suzy Van Sanden, Alexandra Jurgens,
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 5003-5003
European Urology Oncologyno. 3 (2023): 447-455
TRANSLATIONAL RESEARCH (2023): 68-79
Elena Castro,Daniela Correia Salles,Rebeca Lozano,Heather Thorne,Isabel Aragon, Fernando Lopez Campos,Jose Rubio, Ana Gutierrez Pecharroman, Daniel Prieto,Isabel García,Maria I Pacheco,Casilda Llacer Perez,
Cancer Cellno. 4 (2020): 584-584
Load More
Author Statistics
#Papers: 82
#Citation: 2342
H-Index: 28
G-Index: 48
Sociability: 6
Diversity: 3
Activity: 24
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn